{"id":33422,"date":"2025-05-14T15:48:57","date_gmt":"2025-05-14T07:48:57","guid":{"rendered":"https:\/\/flcube.com\/?p=33422"},"modified":"2025-05-14T15:48:58","modified_gmt":"2025-05-14T07:48:58","slug":"zhongsheng-pharmas-anruiwei-shows-promising-results-in-pediatric-influenza-a-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33422","title":{"rendered":"Zhongsheng Pharma’s Anruiwei Shows Promising Results in Pediatric Influenza A Study"},"content":{"rendered":"\n

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317<\/a>) announced the topline analysis data from the Phase II study of its Category 1 drug candidate Anruiwei (ZSP1273, onradivir) in pediatric and adolescent patients with simple influenza A (ages 2-17 years).<\/p>\n\n\n\n

Clinical Trial Results<\/strong>
The results indicated that both the median time to relief of influenza symptoms and the median time to resolution of fever were numerically shorter in pediatric patients compared to adult patients in the Phase III trial. The reduction in viral RNA load and the time to viral clearance were also comparable to the virological data from adult patients in the Phase III trial.<\/p>\n\n\n\n

Conclusion<\/strong>
These preliminary findings suggest that onradivir demonstrates positive efficacy outcomes in both clinical symptoms\/signs and virological aspects when treating influenza A in pediatric and adolescent participants aged 2-17 years.-Fineline Info & Tech<\/a><\/p>\n\n\n\n